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Background: Increasing evidence suggests a mechanistic link between the glycemic environment and renal and
cardiovascular events, even below the threshold for diabetes. We aimed to assess the association between HbA1c
and chronic kidney disease (CKD) and cardiovascular disease (CVD).
Methods: A cross-sectional study involving a random representative sample of 2270 adults from southern Spain
(Malaga) was undertaken. We measured HbA1c, serum creatinine and albuminuria in fasting blood and urine samples.
Results: Individuals without diabetes in the upper HbA1c tertile had an unfavorable cardiovascular and renal profile
and shared certain clinical characteristics with the patients with diabetes. Overall, a higher HbA1c concentration was
strongly associated with CKD or CVD after adjustment for traditional risk factors. The patients with known diabetes had
a 2-fold higher odds of CKD or CVD. However, when both parameters were introduced in the same model, the HbA1c
concentration was only significantly associated with clinical endpoints (OR: 1.4, 95% CI, 1.1-1.6, P = 0.002). An increase in
HbA1c of one percentage point was associated with a 30% to 40% increase in the rate of CKD or CVD. This relationship
was apparent in persons with and without known diabetes. ROC curves illustrated that a HbA1c of 37 mmol/mol (5.5%)
was the optimal value in terms of sensitivity and specificity for predicting endpoints in this population.
Conclusion: HbA1c levels were associated with a higher prevalence of CKD and CVD cross-sectionally, regardless of
diabetes status. These data support the value of HbA1c as a marker of cardiovascular and renal disease in the general
population.
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Chronic kidney disease (CKD), evidenced by either albu-
minuria or decreased kidney function, is increasing
worldwide, especially in individuals with metabolic ab-
normalities, including dysglycemic disorders [1,2]. In
addition, much research has demonstrated a significant
relationship between components of the cardiometabolic
syndrome and both CKD and cardiovascular disease
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distribution, and reproduction in any mediumor hypertension [3-6]. Given this background, a mechan-
istic link between metabolic abnormalities and adverse
renal and cardiovascular events seems likely.
The glycated hemoglobin concentration (HbA1c) is a
useful indicator of mean blood glucose concentrations
over the preceding 3 months, but it may also unmask
dysglycemic disorders, including the prediabetic state.
Epidemiological studies have reported that higher
HbA1c values were strongly associated with microvascu-
lar diabetic complications, and CVD and all-cause mor-
tality in populations with and without diabetes [7-11].
However, the linear relationship between HbA1c con-
centrations and the presence of CKD in the general
population has not been fully elucidated, even when atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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cardiovascular morbidity and mortality has been associ-
ated with albuminuria and/or reduced kidney function,
regardless of age [14]. Thus, screening of HbA1c con-
centrations in the general population could be crucial to
identify different HbA1c phenotypes associated with
CKD and CVD, even in the absence of diabetes.
Cardiovascular morbidity and mortality rates are not
uniform throughout European countries. A higher
prevalence of cardiovascular risk factors, especially
dyslipidemia and obesity, has been reported in southern
Spain [15,16].
The aim of this study, therefore, was to assess the rela-
tionship between HbA1c concentrations and CKD and
CVD in an adult urban Mediterranean population from
southern Spain (Malaga).
Methods
This cross-sectional, analytical, epidemiological study
was derived from the IMAP study (Multidisciplinary
Intervention in Primary Care) and involved a random
representative sample of 2270 adults (18–80 years)
assigned to a specific Health Center (n: 29,818 people)
in Malaga city (Spain) in order to determine a HbA1c
cut-off point for CKD and CVD. The methodology of
the IMAP study has been reported previously [16,17].
The participants were located and invited by telephone
to participate in the study. Recruitment was done be-
tween January and June 2007. All the participants under-
went a clinical interview and physical examination, and
provided fasting (≥12 hours) blood and urine samples.
The blood and urine samples were analyzed in the refer-
ence hospital laboratory (Carlos Haya University Hos-
pital) and biochemical determinations were assayed
using conventional techniques. All the clinical informa-
tion and laboratory values were contrasted with chart re-
view over the previous three months. HbA1c was
measured by high performance liquid chromatography
(Adams A1C, HA-8160, ARKRAY Kyoto, Japan) and
standardized according to the criteria of the National
Glycohemoglobin Standardization Program [18].
Fasting plasma glucose levels of <5.6 mmol/L, 5.6-
6.9 mmol/L, and ≥7.0 mmol/L were considered as nor-
mal, impaired fasting glucose, and diabetes, respectively.
Participants were considered to be patients with diabetes
if they had a previous diagnosis of diabetes, were taking
drugs for diabetes, or their HbA1c was ≥48 mmol/mol
(≥6.5%) [19]. CVD was considered to be the presence of
a previous history of coronary heart disease, heart fail-
ure, cerebrovascular disease, aortic aneurysm, or periph-
eral arterial disease. The glomerular filtration rate (GFR)
was estimated using the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) equation [20].
Urine albumin and creatinine were measured from aspot urine sample. Albuminuria was defined as an
albumin-to-creatinine ratio ≥33.8 mg/mmol. Individuals
with an estimated GFR below 60 ml/min/1.73 m2 and/or
albumin-to-creatinine ratio ≥33.8 mg/mmol were con-
sidered to have CKD [21].
Other variables of interest
Blood samples were assayed for total and low-density
lipoprotein cholesterol and uric acid. The body mass
index (BMI) was obtained from measured height and
weight. Obesity was defined as a BMI > 30 kg/m2. Infor-
mation on cigarette smoking was also elicited during the
interview. Resting systolic blood pressure was measured
using a random-zero sphygmomanometer. As the study
sample was not selected, hypertension was defined as a
systolic blood pressure ≥140 mmHg and/or a diastolic
blood pressure ≥90 mmHg, or treatment with antihyper-
tensive drugs.
The study was approved by the Ethics and Research
Committees of Carlos Haya Hospital, Virgen de la
Victoria Hospital, Canary Isles University Hospital,
Ciudad Jardin Health Centre, and La Cuesta Health
Centre, and informed consent was obtained from all the
participants. The study was conducted in accordance
with the Declaration of Helsinki. In addition, reporting
of the study conforms to the STROBE statement along
with references to STROBE and the broader EQUATOR
guidelines [22].
Statistical analysis
HbA1c values were divided into tertiles in order to
analyze the demographic and clinical characteristics of
the population. Quantitative variables are expressed as
the mean ± standard deviation, whereas the qualitative
variables are expressed as percentages. An analysis of
variance (ANOVA) was used to compare quantitative
variables and the χ2 test for qualitative variables. All
probability values were two-tailed and all confidence in-
tervals (CI) were computed at the 95% level. Logistic re-
gression analysis was used to assess the relationship
between CKD or CVD and HbA1c and diabetes. Age
and gender-adjusted odds ratios were calculated in the
entire population. A similar approach was performed
after adjusting for other confounding variables. The
Hosmer-Lemeshow goodness of fit was the principal cri-
terion for selection of the final models. Receiver operat-
ing characteristic (ROC) curves were plotted and the
area under the curve (AUC) was estimated to assess the
predictive performance of HbA1c in discriminating CKD
or CVD. In addition, the best discrimination limit for
HbA1c levels was explored by the maximum of the
Younden’s index (sensitivity + specificity – 1). This cor-
responds to the value where sensitivity plus specificity is
maximized. All computations were carried out using
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and Epidat 3.1. A P value <0.05 was considered
significant.
Results
Overall, CKD and CVD were documented in 5.2% and
4%, respectively, of the individuals without diabetes.
These percentages were higher in the patients with
known diabetes (19.4% and 15.4%, respectively).
Table 1 displays clinical and demographic characteris-
tics for different HbA1c tertiles and known diabetes. As
expected, patients with known diabetes showed a higher
mean HbA1c concentration 56 mmol/mol (7.3 ± 1.4%)
than the rest of the study sample 37 mmol/mol (5.5 ±
0.4%). They were also older and had a worse metabolic,
cardiovascular and renal profile, evidenced by a higher
BMI, blood pressure and plasma lipids, as well as a
lower CKD-EPI than patients without diabetes. Indeed,
cardiovascular disease and CKD were more frequent in
the patients with diabetes. In addition, individuals in the





Age, y. 36 ± 12
Male gender, n (%) 375 (46.5)
Body mass index, kg/m2 25.4 ± 4
Systolic blood pressure, mmHg 121 ± 15
Diastolic blood pressure, mmHg 72 ± 9
Serum creatinine, μmol/l 68 ± 17.5
CKD-EPI, ml/min/1.73 m2 109 ± 17
FPG, mmol/mol 4.7 ± 0.5
HbA1c, mmol/mol (%) 32 (5.1 ± 0.16)
Total cholesterol, mmol/l 3.6 ± 2
LDL-cholesterol, mmol/l 3 ± 0.8
Triglycerides, mmol/l 1 ± 0.6
Uric acid, mmol/l 261.7 ± 77.4
Urinary albumin/creatinine, mg/mmol 10.5 ± 49.7
Dyslipidemia, n (%) 51 (6.3)
Hypertension, n (%) 66 (8.2)
Smoking, n (%) 227 (28)
Cardiovascular disease, n (%) 13 (1.6)
CKD, n (%) 33 (4.1)
Values are expressed as mean ± SD. P < 0.001 for differences between HbA1c tertile
HbA1c values are expressed in IFCC (International Federation of Clinical Chemistry)
Glycohemoglobin Standardization Program) units (%-one decimal). Conversion from
equation: NGSP = [(0.09148 ∗ IFCC) + 2.152].
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equatio
kidney disease.shared a few characteristics with the patients with
diabetes.
Table 2 shows the relationship between HbA1c and
CKD and/or CVD after adjustment for age and gender
only, and then after adjustment for age, gender and
other risk factors. Known diabetes was significantly asso-
ciated with CKD, CVD, or both, with approximately 2-
fold increases. These odds were only slightly attenuated
after adjustment for known risk factors. HbA1c levels
were also independently related to clinical endpoints
after adjustment for traditional risk factors. However,
when known diabetes and HbA1c levels were introduced
in the same model, diabetes was not significantly associ-
ated with CKD or CVD. No interaction was found be-
tween HbA1c concentration and gender (P = 0.503). Of
note, an increase in HbA1c levels of one percentage point
was associated with a 30% to 40% increase in CKD or
CVD. Thus, the significant associations between diabetes
and CKD and CVD seemed to be entirely mediated by the
HbA1c concentration, irrespective of the diabetic status.
Similar significant associations were found between HbA1cA1c tertiles and known diabetes
rtiles
6-39 mmol/mol 40-46 mmol/mol
(5.4-5.7%) (5.8-6.4%) Known diabetes
N = 762 N = 500 N = 201
42.4 ± 14.5 51 ± 15 61 ± 12
390 (51) 364 (52.6) 103 (51)
26.6 ± 5 28.3 ± 5 30.4 ± 5
125 ± 16 128 ± 16 134 ± 18
75 ± 10.4 77 ± 10 77 ± 10
69.8 ± 17.5 70.7 ± 17.5 74.3 ± 25
104 ± 18 98.5 ± 18 86 ± 19
4.9 ± 0.5 5.2 ± 0.6 8.1 ± 0.4
36 (5.5 ± 0.11) 41 (5.9 ± 0.17) 56 (7.3 ± 1.4)
5.2 ± 1.1 5.4 ± 1 5.5 ± 1.1
3.3 ± 0.9 3.5 ± 0.9 3.5 ± 0.9
1.2 ± 0.8 1.3 ± 0.9 1.7 ± 1
279.6 ± 83.3 291.5 ± 77.3 309.3 ± 97.5
9.8 ± 36.2 11.3 ± 21.5 24.8 ± 63.3
96 (12.6) 98 (20) 72 (36)
110 (14.4) 123 (24.6) 104 (52)
222 (29) 133 (26.6) 46 (23)
17 (2.2) 33 (6.6) 31 (15.4)
47 (6.2) 60 (12) 39 (19.4)
s for all variables except for smoking and urinary albumin/creatinine.
units (mmol/mol- no decimal point) followed by NGSP (National
IFCC to NGSP units is provided by the
n; FPG, fasting plasma glucose; LDL, low density lipoprotein, CKD, chronic
Table 2 Logistic regression analysis for chronic kidney disease and cardiovascular disease in the entire study
population based on known diabetes and HbA1c (per 1-percentage point increase)
Dependent
variable
Independent variables Age and sex-adjusted
odds ratio (95% CI)
P value Age, sex and other factor-adjusted*
odds ratio (95% CI)
P value
CKD
Model 1: HbA1c 1.4 (1.2-1.7) 0.000 1.4 (1.2-1.8) 0.000
Model 2: Known diabetes 2.8 (1.8-4.4) 0.000 2.5 (1.5-4) 0.000
Model 3: HbA1c & 1.2 (0.97-1.5) 0.110 1.3 (0.99-1.6) 0.057
known diabetes 2.1 (1.2-3.7) 0.013 1.7 (0.96-3.3) 0.067
CVD
Model 1: HbA1c 1.4 (1.2-1.6) 0.000 1.4 (1.1-1.6) 0.000
Model 2: Known diabetes 1.9 (1.2-3.2) 0.007 1.7 (1.02-2.8) 0.041
Model 3: HbA1c & 1.3 (1.1-1.7) 0.012 1.4 (1.1-1.8) 0.009
known diabetes 1.2 (0.6-2.3) 0.582 0.9 (0.5-1.9) 0.955
CKD or CVD
Model 1: HbA1c 1.5 (1.3-1.7) 0.000 1.5 (1.3-1.7) 0.000
Model 2: Known diabetes 2.6 (1.8-3.8) 0.000 2.3 (1.5-3.3) 0.000
Model 3: HbA1c & 1.3 (1.1-2.6) 0.004 1.4 (1.1-1.6) 0.002
known diabetes 1.6 (0.9-2.7) 0.053 1.3 (0.8-2.3) 0.250
*Other factors include blood pressure, body mass index, smoking, dyslipidemia, uric acid, and cardiovascular disease.
Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease.
Figure 1 ROC curve for HbA1c as a predictor of chronic kidney
disease or cardiovascular disease in the entire study
population. The optimal predictor cut-off value (*) was that of the
highest sensitivity together with the lowest number of false
positives (specificity). This value corresponds to 37 mmol/mol (5.5%).
ROC curve area: 0.76 (95% CI, 0.71-0.80).
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betic (odds ratio 1.03, 95% CI 1.03-1.6, P = 0.025) and non-
diabetic populations (odds ratio 1.1, 95% CI 1.1-3.4, P =
0.010). Finally, fasting glucose levels were similarly associ-
ated with CKD or CVD (odds ratio 1.011, 95% CI 1.005-
1.017, P < 0.001) when they were entered into the multi-
variate model instead of the HbA1c concentration.
Figure 1 shows the ROC curve for HbA1c levels and
the endpoints in the entire study population. The AUC
for the HbA1c concentration to predict CKD or CVD
was 0.76 (95% CI, 0.71-0.80). The best Younden’s index
was 0.37 for the HbA1 cut-off levels. The optimal value
for HbA1c was 37 mmol/mol (5.5%), which gave a sensi-
tivity of 82% and a specificity of 55%. We performed an
additional analysis in individuals without diabetes (n =
2069). An HbA1c of 37 mmol/mol (5.5%) had less sensi-
tivity (73%) and a similar specificity (60%) for clinical
endpoints.
Discussion
This study provides evidence for concluding that HbA1c
may be a useful biomarker to identify individuals at risk
for cardiovascular and renal disorders in the general
population. Indeed, in this adult Mediterranean
community-based population, we elucidated an HbA1c
phenotype associated with CKD and CVD, even below
the threshold commonly accepted for the diagnosis of
diabetes. Similar associations were observed with fasting
glucose levels, but HbA1c strongly correlates with the
level of ambient glycemia during a 2 to 3 month period,so that it reflects the usual daily fasting and postprandial
glucose levels as established by the American Diabetes
Association (ADA) [19]. Since a high prevalence of car-
diovascular risk factors has been recently reported in
this particular population [15,16], these findings may be
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order to prevent or delay CKD and CVD.
Previous studies have reported that higher values of
HbA1c are a powerful predictor of CVD and all-cause
mortality in populations with and without diabetes
[7-10]. In addition, a poor glycemic control, evidenced
by higher HbA1c levels, has been associated with CKD
in patients with diabetes, even in the absence of albu-
minuria and retinopathy [10,11]. However, whether the
HbA1c concentration is related to the presence of CKD
in the general population, regardless of the diabetic sta-
tus, has been explored less [12,13].
In our study, we observed a strong and linear cross-
sectional association between the HbA1 concentration
and CKD and CVD. An increase in HbA1c levels of one
percentage point was associated with a 30% to 40% in-
crease in CKD or CVD. This association was independent
of traditional factors associated with CKD and CVD, in-
cluding diabetic status. Moreover, higher HbA1c levels
were more strongly associated with the clinical endpoints
other than diabetes when a composite endpoint (CKD or
CVD) was considered in our multivariate analysis. Similar
statistical associations were also observed in the subsets of
diabetic and non-diabetic patients. It is plausible, there-
fore, that the increase in these clinical endpoints seemed
to be mediated by the HbA1c level. In other words, the
degree of hyperglycemia, rather than the presence or ab-
sence of diabetes as such, could be related to future car-
diovascular or renal events. As an example, a HbA1c level
≤48 mmol/mol (6.5%) in an individual without diabetes
may predict a higher likelihood of CKD or CVD than a
HbA1c level of 37 mmol/mol (5.5%) in a patient with
well-controlled diabetes. Further prospective studies are
needed to clarify this issue.
Given our results, a lower threshold HbA1c concentra-
tion for detecting CKD or CVD seems likely. A HbA1c
cut-off point of 37 mmol/mol (5.5%) proved to be the
optimal predictor of composite endpoints in our study
population, similar to that reported in community-based
populations of adults without diabetes [8,9]. This cut-off
value is close to the 39 mmol/mol (5.7%) figure, which
has been retained by the ADA for defining the persons
at high risk for developing type 2 diabetes [19]. In
addition, our individuals without diabetes in the higher
HbA1c tertile showed a worse cardiovascular and renal
profile than the rest and shared various clinical charac-
teristics of the metabolic syndrome with the patients
with diabetes [17]. Given that the upper HbA1c limit in
these patients was 6.4%, we cannot rule out that a predi-
abetic status could have a negative impact in our study,
as reported by others [8]. Our findings suggest that con-
comitant metabolic risk factors may partly explain some
of the mechanisms associated with CKD or CVD in this
population from southern Spain. The fact that anincreasing prevalence of metabolic risk factors has been
strongly associated with a higher prevalence of CKD and
CVD in the general population supports this hypothesis
[3,4,23]. Whatever the case, whether lowering HbA1c de-
creases cardiovascular and renal events in this high-risk
population deserves to be investigated by clinical trials.
A mechanistic relation between cardiorenal events
could be established in these patients. The presence of
insulin resistance and multiple risk factors has been as-
sociated with CKD in the general population without
diabetes [24]. A growing body of evidence suggests that
several pathophysiologic pathways may mediate the toxic
effects of glucose fluctuations. The glycemic environ-
ment has been found to be proatherogenic through
chronic inflammation [25,26]. Furthermore, HbA1c may
be a link between chronic hyperglycemia and oxidative
stress and endothelial dysfunction. HbA1c is a target for
intracellular glycoxidation and peroxidation reactions
that result in the formation of advanced glycation end
products [27], which are implicated in the initiation and
progression of atherosclerosis. Lastly, changes in gly-
cemia may induce activation of growth factors, which
may contribute to the development of intraglomerular
hypertension and renal injury [28]. Taken together, these
metabolic pathways may explain the relationship be-
tween HbA1c and microvascular and macrovascular
complications in the general population, including per-
sons with a prediabetic status. Whether new markers of
glycemia, such as glycated albumin, may reflect a stron-
ger association remains to be determined.
This study has a few limitations. The cross-sectional
design of the study does not allow us to elucidate the
temporal direction of the associations observed between
HbA1c and CKD and CVD, nor the exposure risk, which
would be better evaluated with a longitudinal study.
Thus, whether HbA1c concentrations and CKD and
CVD are causally related cannot be concluded from this
cross-sectional study. In addition, the prevalence rates of
CKD and CVD seen in this study were low. However,
our study involved a random and representative sample
of the adult population from southern Spain. Future lon-
gitudinal studies derived from this study should clarify
this point. Secondly, the population studied was exclu-
sively Caucasian; thus, the results cannot be extrapolated
to other populations with differing diets or lifestyles. Fi-
nally, we only performed a single blood extraction for
the diagnosis of diabetes based on glycemic indexes.
Nevertheless, as the short-term reproducibility of HbA1c
levels is very high [29], a second measurement would
not provide a significantly different result. In addition,
the interpretation of an isolated measurement of fasting
plasma glucose and HbA1c values represents daily prac-
tice in clinical decision making and has been used in
other population studies [7-9].
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In conclusion, this community-based epidemiological
study highlights the independent association between
HbA1c levels and CKD and CVD, regardless of the dia-
betes status. Very small shifts in the average HbA1c level
of the general population could significantly affect the
future incidence of cardiovascular and renal events in
longitudinal studies. These data add to the evidence
supporting screening of the HbA1c concentration in the
general population to identify cut-off points associated
with CKD and CVD in the clinical setting, even in the
absence of diabetes.
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